Important note: Information in this article was accurate in 1991. The state of the art may have changed since the publication date.
AN ASSAY FOR THE DETECTION OF HIV SEROPOSITIVE INDIVIDUALS BASED ON A CHEMICALLY SYNTHESIZED PEPTIDE
HIV Detection by Genetic Engineering Methods. Luciw PA and Steimer KS, eds. New York, Marcel Dekker, p. 161-7, 1989.. Unique Identifier : AIDSLINE ICDB/90660260 Cosand WL; Houghton RL; Goldstein LC; Oncogen, Seattle, WA
Abstract:
An HIV-antibody immunoassay is described that employs peptide 39, which corresponds to amino acids 584-609 of the env precursor protein of the Bru LAV strain of HIV. Peptide 39 was synthesized by solid phase methodology. Serum or plasma samples were defined as seropositive or negative by the LAV EIA (Genetic Systems) and radioimmunoprecipitation. In ELISAs, peptide 39 detected all but one of 265 positive samples and had one false-positive among 174 negative sera (99.6% sensitivity and 99.4% specificity). A test based on this peptide was also able to detect seroconversion in an animal as early as the commercial test based on disrupted virus. Sequential blood samples taken from a chimpanzee following infection with HIV were assayed for viral antigen (a capture assay), for anti-HIV antibody (the commercial LAV EIA test), and for reactivity in the peptide 39 ELISA. No antibody was detectable during the initial period of antigenemia. Six wk after infection, antigen could no longer be detected, presumably because it was present only in immune complexes or because the viral proteins had been cleared from the blood. Antibody to peptide 39 and the disrupted virus was detected clearly at 4 wk and continued to increase until 10 or 12 wk postinfection. A peptide assay that combined peptide 39 with peptides from gag proteins might be used to replace the virus in current ELISA screening assays and might offer advantages in cost, safety, and manufacturing reliability, as well as in sensitivity and specificity. (18 Refs)
Keywords: Amino Acid Sequence AIDS Serodiagnosis/*METHODS *Cloning, Molecular Human HIV/*GENETICS/IMMUNOLOGY HIV Antibodies/ANALYSIS HIV Antigens/*GENETICS/IMMUNOLOGY HIV Envelope Protein gp41/*GENETICS/IMMUNOLOGY HIV Seropositivity/*DIAGNOSIS/IMMUNOLOGY Peptides/*GENETICS/IMMUNOLOGY MONOGRAPH 910228
M9120720
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Important note: Information in this article was accurate in 1991. The state of the art may have changed since the publication date.
